- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04054050
Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis
January 9, 2024 updated by: Johns Hopkins University
Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life.
Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects on a subtype of retinal ganglion cells that help regulate circadian rhythms and sleep.
This pilot study will evaluate whether, in people with MS, bright light therapy reduces sleep disturbance and explore whether light therapy improves function of these cells.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Multiple sclerosis (MS), an inflammatory and neurodegenerative disorder of the central nervous system (CNS), is the most common cause of progressive neurologic dysfunction in early to middle adulthood.
People with MS are a markedly high risk for sleep disturbance.
Estimates of the lifetime prevalence of sleep disturbance in MS reach 50%; sleep disturbance is also associated with excess MS-associated morbidity and diminished quality of life.
Despite the high burden of impaired sleep and its contribution to adverse MS outcomes, effective approaches to treat and ameliorate disturbed sleep in people with MS remain poorly understood.
There is unmet need to develop safe and effective rehabilitative alternatives to mitigate sleep disturbance in MS.
Prior research supports the use of timed bright light therapy (LT) as one such approach for insomnia and sleepiness in those with sleep disorders or other neurologic diseases.
Yet, the safety and potential effectiveness of timed LT have yet to be tested in MS.
The goal of the proposed study is to conduct a detailed intervention study testing if timed bright LT in people with MS is 1) safe (primary outcome) and 2) potentially effective for reducing sleep disturbance (specifically, reducing insomnia, fatigue and improving sleep efficiency, quantity and quality as secondary outcomes).
The study will also explore whether LT stimulates a novel subtype of retinal ganglion cells which are central to the regulation of circadian rhythms and sleep.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of MS
- Evidence of sleep disturbance
- Stable on immunomodulatory MS therapy or no therapy for at least 6 months prior to study initiation
- Stable on antidepressants for at least 3 months prior to study initiation and no evidence
- Stable on fatigue medication for at least 3 months prior to study initiation
- Willing and able to provide informed consent and follow study procedures.
Exclusion Criteria:
- Evidence of cognitive impairment
- Low risk for sleep disordered breathing
- Other comorbid ophthalmologic disorders (e.g. cataracts, glaucoma, blindness)
- Traveled across two time zones within 90 days of study screening.
- Not participating in shift work
- MS relapse or history of acute optic neuritis within 30 days
- No prior history of bipolar disorder
- No evidence of current depression
- Diagnosis of severe periodic limb movement disorder or severe restless legs syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Light therapy
Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
|
Bright light (10,000 lux) therapy will be administered via a light box.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: 2 weeks
|
The number of adverse events will be documented and categorized by organ system
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sleep quantity as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, 2 weeks
|
The PSQI has a sub-component that quantifies sleep quantity.
The investigators will assess change in sleep quantity (difference in minutes) as assessed by this sub-component.
|
Baseline, 2 weeks
|
Change in sleep efficiency as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, 2 weeks
|
The PSQI has a sub-component that quantifies sleep efficiency.
The investigators will assess change in sleep efficiency (difference in minutes) as assessed by this sub-component.
|
Baseline, 2 weeks
|
Change in overall sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, 2 weeks
|
The PSQI has an overall score that ranges from 0 to 21.
The investigators will assess change in the overall PSQI score.
|
Baseline, 2 weeks
|
Change in sleep efficiency as assessed by actigraphy
Time Frame: Baseline, 2 weeks
|
Change in sleep efficiency is calculated as time sleeping divided by time in bed which is measured by actigraphy.
|
Baseline, 2 weeks
|
Change in total sleep time
Time Frame: Baseline, 2 weeks
|
Change in total sleep time (minutes) as quantified by actigraphy
|
Baseline, 2 weeks
|
Change in insomnia severity as assessed by the Insomnia Severity Index (ISI)
Time Frame: Baseline, 2 weeks
|
The ISI is validated questionnaire assessing insomnia from which a total score is calculated and ranges from 0 to 28.
The investigators will calculate change in the overall ISI score.
|
Baseline, 2 weeks
|
Change in daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS)
Time Frame: Baseline, 2 weeks
|
The ESS is validated questionnaire assessing daytime sleepiness from which a total score is calculated and ranges from 0 to 24.
The investigators will calculate change in the overall ESS score.
|
Baseline, 2 weeks
|
Change in fatigue severity as assessed by the Neuro-QoL fatigue questionnaire
Time Frame: Baseline, 2 weeks
|
The Neuro-QoL fatigue severity score (short form) is a validated 8-question assessment of fatigue from which T-scores ranging from 0 to 100 can be obtained.
The investigators will assess change in Neuro-QoL fatigue severity.
|
Baseline, 2 weeks
|
Change in function of intrinsically photosensitive retinal ganglion cells
Time Frame: Baseline, 2 weeks
|
Change in function of intrinsically photosensitive retinal ganglion cells as quantified by the relative change in pupillary light response to blue light.
|
Baseline, 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathryn C Fitzgerald, ScD, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2021
Primary Completion (Estimated)
January 30, 2025
Study Completion (Estimated)
January 30, 2025
Study Registration Dates
First Submitted
August 9, 2019
First Submitted That Met QC Criteria
August 9, 2019
First Posted (Actual)
August 13, 2019
Study Record Updates
Last Update Posted (Actual)
January 10, 2024
Last Update Submitted That Met QC Criteria
January 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00222887
- R03HD101056 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be available to other researchers.
Since the study will enroll only 24 individuals, even if stripped of identifiers, it may still be possible to identify participants.
Thus, data will not be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Light therapy
-
University of HoustonCompleted
-
University of Colorado, BoulderRecruiting
-
University Hospital, Strasbourg, FranceCompleted
-
Uppsala UniversityUppsala County Council, SwedenCompletedDelayed Sleep Phase SyndromeSweden
-
Northwestern UniversityRecruitingAging | Peripheral Vascular Disease | Peripheral Artery Disease | Walking, DifficultyUnited States
-
Massachusetts General HospitalLiteCure LLCCompletedDepression | Major Depressive DisorderUnited States
-
Chinese University of Hong KongRecruiting
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São Paulo; Centro de Pequisas de...Completed
-
Medical University of ViennaCompletedSeasonal Affective DisorderAustria
-
The Netherlands Cancer InstituteDutch Cancer SocietyCompletedHodgkin Lymphoma | Diffuse Large B Cell LymphomaNetherlands